N@N

SHIRE PLC-ADR (NASDAQ:SHPGY), Up By 8.76% ($8.23) From $93.990 After BUYINS.NET Report Predicted Strength After Earnings

^{Published on 2011-07-27 07:21:27 - WOPRAI}
 

July 27, 2011 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Wednesday, April 27th 2011 stating that SHIRE PLC-ADR (NASDAQ:SHPGY) was expected to be Up After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=shpgy&id=163135

At the time this story was written, SHIRE PLC-ADR (NASDAQ:SHPGY) is Up By 8.76% ($8.23) From $93.990 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

SHIRE PLC-ADR (NASDAQ:SHPGY) - Shire plc, a specialty biopharmaceutical company, engages in the research and development, manufacture, sale, and distribution of pharmaceutical products. It operates in two segments, Specialty Pharmaceuticals and Human Genetic Therapies. The Specialty Pharmaceuticals segment offers products for the treatment of attention deficit and hyperactivity disorder, including VYVANSE, a pro-drug stimulant; INTUNIV, an alpha-2A receptor; EQUASYM; and ADDERALL XR. It also produces PENTASA and LIALDA/MEZAVANT for the treatment of active ulcerative colitis; and RESOLOR, which is 5-HT4 receptor agonist that stimulates gastrointestinal motility. In addition, this segment provides FOSRENOL for use in end-stage renal failure patients receiving dialysis; CALCICHEW, a range of calcium and calcium/vitamin D3 supplements; CARBATROL, an anti-convulsant for individuals with epilepsy; REMINYL/REMINYL XL for the symptomatic treatment of dementia of the Alzheimer type; and XAGRID for the reduction of elevated platelet counts, as well as for the treatment of thrombocythemia. The Human Genetic Therapies segment offers REPLAGAL for Fabry disease; ELAPRASE for the treatment of hunter syndrome; FIRAZYR for hereditary angioedema; and VPRIV for the treatment of type 1 Gaucher disease. The company also licenses its patented antiviral products for human immunodeficiency virus and Hepatitis B. In addition, it is developing various products in the areas of attention deficit hyperactivity disorder, human genetic therapies, and gastrointestinal diseases, as well as in other therapeutic areas. The company markets its products through distributors in North America, the Republic of Ireland, the United Kingdom, and internationally. It has collaboration agreements with Santaris Pharma A/S, Renovo Limited, and Acceleron Pharma, Inc. Shire plc was founded in 1986 and is based in Dublin, Ireland.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. SHIRE PLC-ADR (NASDAQ:SHPGY) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net